Henry Schein (HSIC) : Waverton Investment Management Ltd scooped up 21,447 additional shares in Henry Schein during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 12, 2016. The investment management firm now holds a total of 38,731 shares of Henry Schein which is valued at $6,143,899.Henry Schein makes up approximately 0.42% of Waverton Investment Management Ltd’s portfolio.
Other Hedge Funds, Including , Simplex Trading added HSIC to its portfolio by purchasing 1,003 company shares during the most recent quarter which is valued at $162,255. Henry Schein makes up approx 0.02% of Simplex Trading’s portfolio.Eqis Capital Management boosted its stake in HSIC in the latest quarter, The investment management firm added 134 additional shares and now holds a total of 1,773 shares of Henry Schein which is valued at $286,056. Henry Schein makes up approx 0.02% of Eqis Capital Management’s portfolio.
Henry Schein closed down -4.41 points or -2.70% at $158.63 with 9,83,393 shares getting traded on Tuesday. Post opening the session at $164.22, the shares hit an intraday low of $158.17 and an intraday high of $164.48 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Henry Schein reported $1.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $1.63. The company had revenue of $2872.60 million for the quarter, compared to analysts expectations of $2845.09 million. The company’s revenue was up 9.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.46 EPS.
Many Wall Street Analysts have commented on Henry Schein. Henry Schein was Upgraded by Goldman to ” Buy” on Oct 11, 2016. Henry Schein was Initiated by BofA/Merrill to “Buy” on Sep 12, 2016.
Henry Schein Inc. provides health care products and services to office-based dental animal health and medical practitioners. The Company operates its business through two segments: health care distribution and technology and value-added services. The health care distribution segment distributes consumable products laboratory products equipment repair services branded and generic pharmaceuticals vaccines surgical products diagnostic tests infection-control products and vitamins among others. The Company’s global technology and value-added services segment provides software technology and other value-added services to health care practitioners. Its offerings include practice management software systems for dental and medical practitioners and animal health clinics. Its value-added practice solutions include financial services on a non-recourse basis e-services practice technology network and hardware services as well as continuing education services for practitioners.